Alnylam Pharmaceuticals Inc (ALNY)vsProtagonist Therapeutics Inc (PTGX)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
PTGX
Protagonist Therapeutics Inc
$104.31
+3.90%
HEALTHCARE · Cap: $6.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 7971% more annual revenue ($3.71B vs $46.02M). ALNY leads profitability with a 8.5% profit margin vs -282.8%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
PTGX
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for PTGX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Earnings expanding 351.3% YoY
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Trading at 10.6x book value
ROE of -20.2% — below average capital efficiency
Revenue declined 95.6%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : PTGX
The strongest argument for PTGX centers on EPS Growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : PTGX
The primary concerns for PTGX are Price/Book, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while PTGX is a turnaround play — different risk/reward profiles.
PTGX carries more volatility with a beta of 2.24 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 28/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Protagonist Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?